Introduction {#Sec1}
============

Selective decontamination of the digestive tract (SDD) is both one of the most studied and one of the most debated preventive measures for critically ill patients in intensive care units (ICUs) (see box). After the first trials in hematology patients in the 1970s \[[@CR1], [@CR2]\], the concept was introduced in ICU populations in the 1980s \[[@CR3]\], and frequently studied in the following decade \[[@CR4]\]. Various different regimens were studied, including strictly oropharyngeal decontamination \[selective oropharyngeal decontamination (SOD)\] (see box). At the turn of the century there were more than 50 randomized, though mostly small and single-center, trials and several meta-analyses. The summarized conclusions from these studies were that SDD was associated with reductions of respiratory tract infections in ICUs with low levels of antibiotic resistance, but that improvement of patient outcome (i.e., better ICU survival) could be demonstrated in meta-analyses only \[[@CR5], [@CR6]\].

Since that time, numbers of new SDD studies declined and this measure was not widely adopted in European ICUs, mainly because the evidence for better patient outcome was considered not convincing, and because of the unknown---possibly detrimental---effects of prophylactic antibiotic use on antibiotic resistance development. The Netherlands became the exception to this rule, due to two studies, both demonstrating survival benefits of patients receiving SDD \[[@CR7], [@CR8]\]. In both studies, SDD was used as a unit-wide intervention in ICUs with low prevalence of antibiotic-resistant bacteria, and in both studies SDD was associated with lower, instead of higher, rates of antibiotic resistance. However, the absolute 28-day mortality reduction in the largest study was 3.5% (relative reduction was 13%) and only determinable in a random-effects logistic regression model with adjustment for baseline differences between study groups \[[@CR8]\]. Moreover, in the latter study, SDD was equally effective in improving patient outcome as SOD.

The beneficial results of SDD and SOD obtained in Dutch ICUs raise the question of whether both measures could be equally beneficial in other European countries. Here, we address some methodological issues relevant to future attempts to quantify the effects of SDD or SOD in critically ill patients.

Study design {#Sec2}
============

The two studies in which SDD was associated with improved patient outcome tested SDD as a unit-wide intervention. In one study, SDD was administered to all patients who provided informed consent in one ICU during a 2-year study period (*n* = 466), and results were compared with those of another ICU (in the same hospital) where none of the patients received SDD (*n* = 468) \[[@CR7]\]. Allocation of patients to either of the two wards was randomized if both units had beds available, but this was not further specified. In the other study, SDD was also administered to all patients eligible during a 6-month period in 13 ICUs (*n* = 2,045), and the results were compared with those obtained in 6-month periods in which all patients received either SOD (*n* = 1,904) or no topical antibiotics (*n* = 1,990) \[[@CR8]\]. The latter was---at that time---considered standard of care. In this cluster-randomized crossover study, each of the 13 ICUs used SDD, SOD, and standard care during 6-month periods, with the order of interventions randomized per center. Importantly, in the latter study, there was no individualized randomization, which bears the risk, intrinsic to any cluster-randomized study, of biased patient inclusion \[[@CR9]\]. Therefore, baseline characteristics related to patient prognosis must be included in the analysis.

There is an obvious reason to evaluate SDD and SOD as a unit-wide measure. Both measures aim to reduce bacterial carriage in individual patients, which may influence the risk of acquisition of bacterial colonization (followed by infection) of other patients. This patient dependency might reduce the true effects of interventions when patients with and without SDD (or SOD) are treated in the same unit \[[@CR10]\]. As a result, failure to demonstrate beneficial outcome results in an individual patient randomized study may not reflect true effects when using these measures in all patients.

Outcome measures {#Sec3}
================

A number of outcomes can be measured when studying infection prevention strategies in the ICU, including infection rates and antibiotic use, length of stay or of mechanical ventilation, and mortality rates in the ICU or at a fixed time-point (e.g., 28 days), or ventilator-free days (surviving) at 28 days. Which of these is most appropriate as the primary end-point in decontamination studies? It is widely believed that SDD and SOD exert their effects largely through prevention of respiratory tract infections, such as ventilator-associated pneumonia (VAP). As compared with SOD, the intestinal decontamination part of SDD seems to reduce the occurrence of ICU-acquired bacteremia with Gram-negative bacilli, but it is unlikely that this effect can be determinable in survival differences \[[@CR11]\]. Diagnosing VAP is difficult and relies for an important part on microbiological culture results from respiratory samples \[[@CR12]\]. The topical antibiotics applied in the oropharynx, though, aim to eradicate bacterial colonization of the upper respiratory tract, which will inevitably influence culture results. Only samples obtained from the distal parts of the lung that cannot be reached by the topical antibiotics will provide reliable diagnostic samples. Therefore, unambiguous, patient-centered outcomes such as survival should be used as end-points when evaluating these interventions. Moreover, since recent studies have convincingly demonstrated that the attributable mortality of VAP is much lower than previously assumed, it is difficult to extrapolate a reduction in VAP incidence to improved patient survival \[[@CR13]--[@CR15]\].

What should be the targeted mortality reduction? The relative reduction in 28-day mortality in the Dutch multicenter study was 13% for SDD and 11% for SOD, corresponding to absolute mortality reductions at day 28 of 3.5% and 2.7%, respectively \[[@CR8]\]. Based on these estimates, derived in units with low levels of antibiotic resistance, at least 2,000 patients per intervention group are needed to gain sufficient power. However, it would be highly relevant to determine outcome effects of these interventions on longer time scales, such as 90-day or 1-year survival, which may well enhance the number of patients needed. Furthermore, it is difficult to anticipate the magnitude of the effect on patient outcome in settings with different bacterial ecology, i.e., with higher prevalence of antibiotic-resistant bacteria. If the preventive effects on infection development are similar in such a setting, but attributable mortality of infection is higher because of more infections being caused by antibiotic-resistant bacteria, the effects on patient survival could be larger than those obtained in Dutch ICUs. In contrast, if fewer infections are prevented because of antibiotic resistance, it can be expected that effects on survival will be smaller (or even absent).

Antibiotic resistance {#Sec4}
=====================

The global emergence of antibiotic resistance, especially among Enterobacteriaceae, necessitates enhanced infection control strategies, also in ICUs. In theory, SDD and SOD could have a synergistic effect with basic infection control measures such as hand hygiene and barrier precautions. Reductions of bacterial loads at places frequently contacted by nursing staff (i.e., the respiratory tract region), would reduce the likelihood of cross-transmission. However, the evidence on the effects of SDD on antibiotic resistance is highly conflicting. In settings with low levels of antibiotic resistance, such as Dutch ICUs, SDD and SOD were associated with lower rates of antibiotic-resistant Gram-negative bacteria \[[@CR7], [@CR16]\], and ongoing follow-up studies seem to confirm these findings (M. Bonten, unpublished data).

Less certain are the effects of topical antibiotics in settings with higher levels of resistance. There is---already "old"---evidence that SDD can help to control outbreaks with multiresistant *Klebsiella* strains \[[@CR17]\], and persistently low levels of resistance have been reported from several centers using SDD for prolonged periods of time. In contrast, in some studies, use of SDD was associated with increasing rates of carriage and infections caused by antibiotic-resistant (mostly Gram-positive) pathogens \[[@CR18]--[@CR21]\].

Colistin is one of the antibiotics used in SDD and SOD. The recent rise of infections caused by carbapenem-resistant Gram-negative bacteria makes this agent a last-resort antibiotic. It is therefore imperative to determine the effects of topical use of colistin on resistance development in Gram-negative bacteria. Furthermore, it is unknown whether patients recolonize with resistant bacteria when SDD is discontinued. Another aspect related to antibiotic resistance is the total amount of intravenous antibiotic use. According to the "classical" SDD protocol, all patients should receive intravenous antibiotics during the first 4 days. However, systemic antibiotics are also prescribed to virtually all eligible ICU patients, whether or not they are receiving SOD or no topical prophylaxis at all \[[@CR8]\]. In the Dutch multicenter study, the total use of intravenous antibiotics (including the SDD component) was around 10% lower during SDD and SOD \[[@CR8]\]. It is unknown to what extent such a reduction in systemic antibiotic use may influence resistance development.

Other considerations {#Sec5}
====================

A formal cost--benefit analysis of SDD does not exist. In the Dutch multicenter study it was estimated that the daily antibiotic costs of SDD and SOD were US \$12 and US \$1, respectively \[[@CR8]\]. However, especially the price of amphotericin B has markedly risen in recent years. Today, the commercial price of SDD and SOD would be around €200 and €40 per day, respectively. Since the necessity of amphotericin B as a component of SDD has never been determined, it might be worthwhile to investigate SDD with other topical antimycotic agents (e.g., nystatin) \[[@CR22]--[@CR25]\].

Based on the Dutch multicenter study, one could conclude that SOD and SDD are equally effective in improving patient outcome. If confirmed, this implies that the improved outcome essentially results from the effects of the strategy on oropharyngeal bacterial carriage. Chlorhexidine oropharyngeal care has also been associated with a 50% reduction in VAP \[[@CR26]\], quite similar to the reported effects of SOD \[[@CR27]\], but the two interventions have never been compared directly. A recent meta-analysis suggests a dose--response relationship with optimal preventive effects of chlorhexidine oropharyngeal care when using a concentration of 2% \[[@CR28]\]. If chlorhexidine is indeed equally effective as SDD and SOD, it would overcome all the potential problems with using topical antibiotics for prophylaxis in critically ill patients.

Future studies {#Sec6}
==============

Currently, there is only one large randomized clinical trial registered which evaluates the effects of SDD or SOD, again in Dutch ICUs (Table [1](#Tab1){ref-type="table"}). Based on the favorable results obtained in Dutch ICUs, the logical next step seems to investigate SDD and SOD in settings with different bacterial ecology. However, when preparing such studies, some important lessons can be learned from the former studies. The beneficial effects of the interventions tested in individual studies have only been apparent when applied as unit-wide interventions. It is, therefore, advisable to apply this approach in any further study. Because of the difficulties in objectively diagnosing VAP and the fact that SDD and SOD cannot be applied in a double-blind manner, it is advisable to use an unambiguous primary outcome, such as patient survival. Considering the small absolute reduction in 28-day mortality derived in Dutch ICUs, study groups should include at least 2,000 subjects. Detailed monitoring of antibiotic resistance is imperative, especially for colistin resistance; finally, studies comparing these interventions with 2% chlorhexidine oropharyngeal care are warranted.Table 1Registered trials (<http://www.clinicaltrials.gov>, M. Bonten, personal communication)StudyYearInstitutePatientsDesignPrimary objectiveInterventionStudy statusMicrobiologic effect of selective decontamination of the digestive tract with colistin, gentamicin, and nystatin2007University of Pittsburgh Pennsylvania40ObservationalEffect of SDD on vancomycin-resistant enterococci colonizationSDD (colistin, gentamicin, nystatin)Not started, terminatedSelective digestive decontamination in carriers of carbapenem-resistant *Klebsiella pneumoniae*2008Soroka University Medical Center, Israel*Unknown*Blinded RCTEffect of SDD on carbapenem-resistant *Klebsiella*SDD (gentamicin and polymyxin E)CompletedThe effects of SDD and SOD on antibiotic resistance in the ICU2009University Medical Center Utrecht, Utrecht, The Netherlands10,000Randomized crossover multicenter trialEffect of SDD and SDD on antimicrobial resistanceSDD and SOD (amphotericin B, tobramycin, colistin, and cefotaxim in SDD)RunningResistant Gram-negative bacteria after cessation of SDD or SOD in ICU patients2010Leiden University Medical Center, Leiden, The Netherlands1,200Prospective observational multicenter trialRectal colonization with any resistant aerobic Gram-negative bacteria at any time point within 10 days after ICU dischargeSDD and SOD (amphotericin B, tobramycin, colistin, and cefotaxim in SDD)RunningR-GNOSIS: Decolonization strategies in intensive care2011University Medical Center Utrecht, Utrecht, The Netherlands10,400Randomized crossover multicenter trialEffect of SDD, SOD, and chlorhexidine mouthwash on Gram-negative bacteremia rateSDD and SOD (amphotericin B, tobramycin, colistin) and chlorhexidine 2%Prior to participant recruitment![](134_2012_2488_Figa_HTML.gif){#d28e585}
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